244 related articles for article (PubMed ID: 9116914)
1. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height.
Weintrob N; Dickerman Z; Sprecher E; Galatzer A; Pertzelan A
Eur J Endocrinol; 1997 Feb; 136(2):188-95. PubMed ID: 9116914
[TBL] [Abstract][Full Text] [Related]
2. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP; Winter A; Stolecke H
Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
[TBL] [Abstract][Full Text] [Related]
3. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I; Kanaka-Gantenbein Ch; Voutetakis A; Maniati-Christidi M; Dacou-Voutetakis C
Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
Pijnenburg-Kleizen KJ; Thomas CMG; Otten BJ; Roeleveld N; Claahsen-van der Grinten HL
J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1055-1063. PubMed ID: 31573958
[TBL] [Abstract][Full Text] [Related]
5. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C; Improda N; Maggioli C; Capalbo D; Roma S; Porzio O; Salerno M; Cappa M
Endocr Pract; 2017 May; 23(5):546-556. PubMed ID: 28225306
[TBL] [Abstract][Full Text] [Related]
6. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia.
Muirhead S; Sellers EA; Guyda H;
J Pediatr; 2002 Aug; 141(2):247-52. PubMed ID: 12183722
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency.
Weintrob N; Brautbar C; Pertzelan A; Josefsberg Z; Dickerman Z; Kauschansky A; Lilos P; Peled D; Phillip M; Israel S
Eur J Endocrinol; 2000 Sep; 143(3):397-403. PubMed ID: 11022183
[TBL] [Abstract][Full Text] [Related]
8. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height.
Jääskeläinen J; Voutilainen R
Pediatr Res; 1997 Jan; 41(1):30-3. PubMed ID: 8979286
[TBL] [Abstract][Full Text] [Related]
9. Compromised Adult Height in Females with Non-Classical Congenital Adrenal Hyperplasia Diagnosed in Childhood.
Bello R; Lazar L; Phillip M; de Vries L
Horm Res Paediatr; 2023; 96(5):465-472. PubMed ID: 36806217
[TBL] [Abstract][Full Text] [Related]
10. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
Lanes R; Gunczler P
Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
[TBL] [Abstract][Full Text] [Related]
11. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty.
Paterson WF; McNeill E; Young D; Donaldson MD
Clin Endocrinol (Oxf); 2004 Nov; 61(5):626-34. PubMed ID: 15521967
[TBL] [Abstract][Full Text] [Related]
12. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
[TBL] [Abstract][Full Text] [Related]
13. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
Bonfig W; Pozza SB; Schmidt H; Pagel P; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3882-8. PubMed ID: 19622620
[TBL] [Abstract][Full Text] [Related]
14. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study.
Hargitai G; Sólyom J; Battelino T; Lebl J; Pribilincová Z; Hauspie R; Kovács J; Waldhauser F; Frisch H;
Horm Res; 2001; 55(4):161-71. PubMed ID: 11598369
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
Van der Kamp HJ; Otten BJ; Buitenweg N; De Muinck Keizer-Schrama SM; Oostdijk W; Jansen M; Delemarre-de Waal HA; Vulsma T; Wit JM
Arch Dis Child; 2002 Aug; 87(2):139-44. PubMed ID: 12138066
[TBL] [Abstract][Full Text] [Related]
16. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China.
Juan L; Huamei M; Zhe S; Yanhong L; Hongshan C; Qiuli C; Jun Z; Song G; Minlian D
J Pediatr Endocrinol Metab; 2016 Jul; 29(7):841-8. PubMed ID: 27054598
[TBL] [Abstract][Full Text] [Related]
17. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
[TBL] [Abstract][Full Text] [Related]
18. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W; Schwarz HP
Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
[TBL] [Abstract][Full Text] [Related]
19. Long-term Growth in Congenital Adrenal Hyperplasia.
Maheshwari A; Khadilkar V; Gangodkar P; Khadilkar A
Indian J Pediatr; 2019 Feb; 86(2):154-158. PubMed ID: 30097840
[TBL] [Abstract][Full Text] [Related]
20. Initial high dose hydrocortisone (HDC) treatment for 21-hydroxylase deficiency (21-OHD) does not affect linear growth during the first three years of life.
Takasawa K; Ono M; Miyai K; Matsubara Y; Takizawa F; Onishi T; Kashimada K; Mizutani S
Endocr J; 2012; 59(11):1001-6. PubMed ID: 22785554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
